Register for email alerts and news feeds:
This journal | BMJ Group
rss
Evidence-Based Medicine 2006;11:169; doi:10.1136/ebm.11.6.169
Copyright © 2006 by the BMJ Publishing Group Ltd.

Therapeutics

Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischaemia

Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665–73.[CrossRef][Medline]

Q In patients with recent minor cerebral ischaemia of arterial origin, is aspirin plus dipyridamole (ASA+DP) more effective than aspirin (ASA) alone for preventing vascular events?

Clinical impact ratings GP/FP/Primary care ******{star} IM/Ambulatory medicine ******{star} Neurology ******* Cardiology ******{star}

Key Words: anti-inflammatory agents (non-steroidal) • aspirin • cerebrovascular accident • dipyridamole • platelet aggregation inhibitors

The first 150 words of the full text of this article appear below.

METHODS

Formula Design: randomised controlled trial (European/Australasian Stroke Prevention in Reversible Ischaemia Trial [ESPRIT]).

Formula Allocation: concealed.*

Formula Blinding: blinded (outcome auditing committee).*

Formula Follow up period: mean 3.5 years.

Formula Setting: 79 hospitals in 11 European countries, Singapore, Australia, and the US.

Formula Patients: 2763 patients (mean age 63 y, 65% men) who had had a minor ischaemic stroke (<=3 on the modified Rankin scale) (66% of patients), transient ischaemic attack (TIA) (28%), or transient monocular blindness (5%) of presumed arterial origin in the previous 6 months. Exclusion criteria included a possible cardiac source of embolism, high grade carotid stenosis, blood coagulation disorder, and limited life expectancy.

Formula Intervention: ASA, 30–325 mg (median 75 mg) daily, plus DP, 200 mg twice daily (83% received the extended release formulation) (n = 1375), or ASA alone (n = 1388).

Formula Outcomes: composite end point of death from all vascular causes, stroke, myocardial infarction, or major bleeding event. Secondary outcomes . . . [Full text of this article]

David Tirschwell, MD, MSc

Harborview Medical Center, Seattle, Washington, USA


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Glossary
Evid. Based Med. 2006 11: 191. (in Glossary) [Extract] [Full Text] [PDF]

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.